Authors


Octave V. Baker

Latest:

Selling successfully to foriegn-born physicians

The growing number of foreign-born physicians in the United States presents both challenges and opportunities for pharmaceutical sales representatives.


Ilyssa Levins

Latest:

Agency Best Practice in Regulatory Compliance

The pharmaceutical industry imposes higher standards on advertising, PR, and medical education agencies than any other industry, except perhaps the financial services sector. Agencies need to keep up with constantly changing rules for advertising and promoting drugs or devices.


Steven W. Mayo

Latest:

Committed to the Quest

It all started because of a commitment I made when I was too young to understand what I was getting myself into. My mother had headaches. Not "throbbing in the temples" headaches, but gut-wrenching, totally incapacitating, "rip the carpet out with your bare hands" headaches. Migraine, cluster headache, trigeminal neuralgia-whatever the flavor, they were really bad. She saw practically every specialist in the country. They gave her ergotamine injections until her fingers turned blue, narcotics powerful enough to stop a charging elephant, and dozens of other medications, many of which were experimental at the time. Nothing worked.


Kenneth I. Kaitin, PhD

Latest:

Meeting Unmet Medical Needs: The Disparity Dilemma

The US drug regulatory system fails to address the country’s most urgent medical needs with the resources appropriate for the task. But change is possible, say Christopher-Paul Milne and Kenneth I. Kaitin.


Paul J. Anderson

Latest:

The Outsider

In his new book, former Lilly CEO Randall Tobias explains his ideas about management. Do they work? He'll have a chance to prove it as he takes the reins of America's $15 billion global campaign against AIDS.



Pam Bailey Marinko

Latest:

Refresher course: office courtesy

Treating other reps well can be good for everyone.


Stan Bernard, MD

Latest:

From Customers to Competitors

"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."



Rob Benson

Latest:

DTC: European Style

In 1996, Sandoz (now Novartis) decided to brave new waters to create consumer demand for the antifungal Lamisil (terbinafine) in the United Kingdom. But with European law forbidding pharma companies to conduct brand-name advertising, Sandoz needed to find another way to encourage patients to talk with their doctors about onychomycosis and its treatment options. So the company re-named the condition the more consumer-friendly "fungal infection" and took out newspaper ads asking readers to call or write to "Step Wise" for a free brochure on foot care.


Julie E. Williamson

Latest:

Economy puts Medicare reform on Hold

Can George W. Bush, Tommy Thompson and Congress agree on how to move forward?


Mike Stone

Latest:

Relationship building: A potent tool

It seems nothing short of amazing to me that the vast majority of pharmaceutical reps bypass what is surely the most potent sales tool that exists. Before I became a provider 22 years ago, I was involved in sales. It was then that I realized that sales are greatly influenced by the nature and quality of the relationships between salespeople and their customers. Failure on the part of pharmaceutical representatives to develop good, strong relationships most often leads to poor prescribing habits on the part of the provider.


Stephen J. Smith

Latest:

Clipping Coupons

In 1894, a druggist named Asa Candler created coupons for Coca-Cola, a new "healthcare" product with "valuable tonic and nerve stimulant properties." After that early start in medical products, coupons developed as a marketing medium and were widely adopted by the consumer packaged goods industry. According to the Promotion Marketing Association's Coupon Council, 336 billion coupons were distributed in 2002, which were redeemed for approximately $3 billion in consumer discounts. Now, more than a hundred years after their debut, consumers are clipping coupons for prescription pharmaceutical products.


Lynda C. McDermott

Latest:

Bridging the Gap

An effective, high-performing alliance can generate a stronger bottom line outcome.


Julie Hall

Latest:

Information Into Action

The key is to convert raw data into actionable intelligence that can enhance operations and improve decision making.


Mark Heitner

Latest:

Internet healthcare

You, the doctor and the sales call.


Jeff Worthington

Latest:

A Matter of Taste

Developing Palatable Medicines for Children is Never Easy, But the Rewards Can Be Great


William D. Novelli

Latest:

Shake Hands on Rx Drugs for Medicare

I received a letter recently from an AARP member in Carrolton, Kentucky, who wrote: ?Medicare will not help seniors with medicine costs. My husband?s a diabetic, has had two heart surgeries and asthma since childhood. He is 68 years old. I am 65 and have congestive heart failure and a lung disease. We have to spend so much on medicine, we barely live?can?t go anywhere except to the doctors and grocery. Please help people like us.?


Peter Keeling

Latest:

Early Engagement with Medical Laboratories

Timely engagement is the key to expanding the use of companion diagnostics.


Jeff Rahmel

Latest:

10 mistakes you should never make in a sales presentation

Most presentation mistakes made by representatives in the field are elementary and may be easily avoided.


Tiffany Mortellito

Latest:

PE's Annual Sales and Marketing Employment Survey: The Big Squeeze

In spite of pharmaceutical employers' best intentions to the contrary, sales rep compensation is being squeezed in a vise that is gradually narrowing the gaps between what top, average, and bottom performers are earning. According to the Hay Group's Pharmaceutical Sales Force Effectiveness Study, co-sponsored by Pharmaceutical Executive, reps in the 90th percentile are earning just 40 percent more than the average performer. This is not to suggest that reps aren't being paid handsomely (they are), but that the pay-for-performance model is showing signs of weakness.


Jean-Patrick Tsang, PhD, MBA

Latest:

Micromarketing An Individual Approach

The computing power of today's PC enables marketers to conduct analyses that were unthinkable just a few years ago, creating exciting new ways to approach and track promotion response. This article describes a novel approach that models promotion response at the individual physician level.


Derek F. Martin

Latest:

Every Employee, Every Day

Pharma companies must address the same group of stakeholders-customers, employees, shareholders-as any other industry, plus one more. Compliance with FDA and other regulatory agencies is not only critical for success, for some life science companies it determines their very survival.


Lyle Berkowitz

Latest:

Internet DTC - Minding Your P's & Q's

Effective DTC Product Web Sites Must Synthesize Advertising and Labeling Requirements


Kevin Daley

Latest:

Try the Socratic approach

Classic tips for earning a customer's trust.


Brent Caslin

Latest:

Can You Keep a Secret?

Pharmaceutical companies big and small depend heavily on information, much of it confidential and valuable. From low-tech customer lists and marketing plans to the coveted results of expensive biotech research, the pharma industry is built on confidential information that must be protected, making the law of trade secrets a key component in a company?s strategy to protect its intellectual property.


James N. Arvesen

Latest:

A Better Way to Manage the Pipeline

A major unresolved issue for the pharmaceutical industry in the 21st century is that few, if any, optimization techniques have found their way into the research portfolio arena.


Jean (Mowrey) Male

Latest:

Things it took a career in sales to learn

Everyone makes mistakes, but it's learning from them, and changing the way we do what we do, that make us successful.


Esther Fleischhacker

Latest:

Bridging the Gap

An effective, high-performing alliance can generate a stronger bottom line outcome.


Robert J. Franco, PhD

Latest:

Beyond the Blockbuster

For decades, blockbuster product development has driven the pharmaceutical industry. Under that model, a handful of products-and, in some cases, a single product-produce the lion's share of revenue and dictate a company's strategic direction. As companies get larger, they rely more and more on blockbusters to sustain their growth. The high cost of developing major, successful drugs only reinforces the need to focus on blockbusters. It's a vicious cycle that remains firmly in place for most Big Pharma.